Cherrywood Campus reposted this
𝐓𝐡𝐞 𝐦𝐨𝐬𝐭 𝐢𝐦𝐩𝐨𝐫𝐭𝐚𝐧𝐭 𝐢𝐧𝐧𝐨𝐯𝐚𝐭𝐢𝐨𝐧 𝐲𝐨𝐮'𝐥𝐥 𝐡𝐞𝐚𝐫 𝐚𝐛𝐨𝐮𝐭 𝐭𝐡𝐢𝐬 𝐰𝐞𝐞𝐤? Part of our Cherrywood Campus community in Dublin, HAON Life Science, is making astonishing strides in neonatal brain injury treatment. Neonatal HIE – a type of newborn brain injury – currently has no available treatment aside from using a cool blanket to drape across the baby. Speaking with BioStock, HAON's Mark O’Neill FCA and Moayed Hamza shared how their platform could deliver the change thousands of parents desperately need. 𝐖𝐚𝐭𝐜𝐡 𝐭𝐡𝐞 𝐢𝐧𝐭𝐞𝐫𝐯𝐢𝐞𝐰 𝐛𝐞𝐥𝐨𝐰 👇
We also had the opportunity to sit down with Moayed Hamza and Mark O’Neill FCA from HAON Life Science, which develops investigational allogeneic candidates for neurologic, rare and other serious diseases. Their first focus indication is neonatal HIE – a type of newborn brain injury – that according to Nature has an incidence that varies between 1 and 3 per 1000 live births in developed countries and 2.3 to 30.6 per 1000 live births in developing countries. Yet, there are no current treatments available aside from cooling. Hamza and O'Neill tells BioStock that their platform is applicable in multiple neurodegenerative diseases, but that they aim for a first approval in neonatal HIE due to its high unmet medical need, lack of competition in the market and thus presents an opportunity for accelerated approval. Hear more about their progress in our interview!